Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned an average rating of "Buy" from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $32.25.

CPRX has been the topic of several analyst reports. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. StockNews.com lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 11th. HC Wainwright increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. Finally, Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an "overweight" rating and a $35.00 target price on the stock.

Catalyst Pharmaceuticals Trading Down 2.1 %

NASDAQ CPRX traded down $0.47 on Thursday, reaching $21.58. The company's stock had a trading volume of 480,524 shares, compared to its average volume of 1,221,015. The firm has a market cap of $2.57 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 3.38 and a beta of 0.80. Catalyst Pharmaceuticals has a 52 week low of $13.49 and a 52 week high of $24.64. The business has a 50-day moving average price of $22.25 and a 200 day moving average price of $21.25.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $27,000. Farther Finance Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC increased its holdings in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. Finally, KBC Group NV boosted its holdings in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Institutional investors own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.